J&J halt Phase III clinical trial

On October 13, 2020, Johnson & Johnson became the second vaccine maker to halt phase III clinical trials while investigators probe whether a participant’s stroke may be linked to the vaccine..  AstraZeneca paused their trials a month earlier.

On October 23, 2020, J&J announced it will resume it’s clinical trails.  “After a thorough evaluation of a serious medical event experienced by one study participant, no clear cause has been identified…the Company has found no evidence that the vaccine candidate caused the event.”